Identification and validation of SRY-box containing gene family member SOX30 methylation as a prognostic and predictive biomarker in myeloid malignancies

Clinical Epigenetics
Jing-Dong ZhouJun Qian

Abstract

Methylation-associated SOX family genes have been proved to be involved in multiple essential processes during carcinogenesis and act as potential biomarkers for cancer diagnosis, staging, prediction of prognosis, and monitoring of response to therapy. Herein, we revealed SOX30 methylation and its clinical implication in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). In the discovery stage, we identified that SOX30 methylation, a frequent event in AML, was negatively associated with SOX30 expression and correlated with overall survival (OS) and leukemia-free survival (LFS) in cytogenetically normal AML among SOX family members from The Cancer Genome Atlas (TCGA) datasets. In the validation stage, we verified that SOX30 methylation level was significantly higher in AML even in MDS-derived AML compared to controls, whereas SOX30 hypermethylation was not a frequent event in MDS. SOX30 methylation was inversely correlated with SOX30 expression in AML patients. Survival analysis showed that SOX30 hypermethylation was negatively associated with complete remission (CR), OS, and LFS in AML, where it only affected LFS in MDS. Notably, among MDS/AML paired patients, SOX30 methylation level was significantly increased i...Continue Reading

References

Jul 9, 2004·Cytogenetic and Genome Research·C DongP Koopman
Nov 28, 2006·Lancet·Elihu Estey, Hartmut Döhner
Sep 10, 2008·Blood·Janet D Rowley
Oct 4, 2008·Blood·Ying JiangJaroslaw P Maciejewski
Dec 24, 2009·Nature Reviews. Cancer·Jianjun ChenJanet D Rowley
Aug 5, 2010·Nature Reviews. Molecular Cell Biology·Susan C Wu, Yi Zhang
Oct 21, 2010·CA: a Cancer Journal for Clinicians·Rodolphe Taby, Jean-Pierre J Issa
Dec 15, 2010·BMC Molecular Biology·Fei HanDeshou Wang
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciHartmut Döhner
May 26, 2012·Blood·Salemiz SandovalKathleen M Sakamoto
Apr 4, 2013·Science Signaling·Jianjiong GaoNikolaus Schultz
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Nov 5, 2013·Cancer Cell·Hong ZhangDaniel G Tenen
Mar 25, 2014·Lancet·Lionel AdèsPierre Fenaux
Jun 24, 2014·Clinical Chemistry and Laboratory Medicine : CCLM·Chun-Yan TangJun Qian
Jul 6, 2014·Blood·Leonie I KroezeUNKNOWN EORTC Leukemia Group and GIMEMA
Oct 1, 2014·Genome Research·Janine O IlaganRobert K Bradley
May 31, 2015·Medical Oncology·Xiang-mei WenJun Qian
Nov 6, 2015·Clinical Epigenetics·Tanja BožićWolfgang Wagner
Jan 29, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Jing YangJun Qian
Nov 20, 2016·British Journal of Haematology·Haixia WanHua Zhong
Apr 30, 2017·Journal of Cellular and Molecular Medicine·Jing-Dong ZhouJun Qian
May 16, 2017·Oncogenesis·S T GuoC C Jiang

❮ Previous
Next ❯

Citations

Jun 9, 2020·Clinical and Translational Medicine·Ting-Juan ZhangJing-Dong Zhou

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS
density-gradient centrifugation
PCR

Software Mentioned

Genomicscape Survival Analysis
GraphPad Prism
CpGplot
GenomicScape
SPSS
DiseaseMeth
Methyl Primer Express

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.